pp-160 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Moderate-to-severe atopic dermatitis; alopecia areata
Clinical stage: Phase 2b
Modality: Biologic (multi-site PEGylated recombinant IL-2 conjugate)
Mechanism / Target: Biased IL-2 receptor agonist — PEG groups block IL-2Rβγ interaction, shifting selectivity towards IL-2Rα (CD25)-expressing Tregs; selectively expands regulatory T cells without effector T-cell or NK-cell activation
Route / form: Subcutaneous injection (weekly or biweekly)
Differentiation: Treg-selective IL-2 may restore immune tolerance in atopic dermatitis; addresses disease mechanism vs symptomatic JAK inhibitors/dupilumab; PEGylation extends half-life and biases selectivity
Manufacturer #39187
Clinical-stage company developing polymer-conjugated cytokines and other novel biologics. Focuses on Treg-selective IL-2 conjugates for autoimmune diseases with differentiated tolerability. Wholly owned atopic dermatitis programme reacquired from former partner.
None